Zevra Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $39,663 | $36,220 | $34,125 | $26,063 |
Gross Profit | 38,138 | 33,955 | 32,605 | 24,510 |
EBITDA | 13,110 | 43,461 | 14,976 | 1,466 |
EBIT | 12,794 | 43,093 | 14,614 | 1,074 |
Net Income | 8,752 | 37,890 | 12,165 | -544 |
Net Change In Cash | 39,663 | 36,220 | 34,125 | 26,063 |
Free Cash Flow | 22,922 | 6,107 | 5,547 | 4,155 |
Cash | 145,321 | 95,595 | 62,406 | 54,439 |
Basic Shares | 61,336 | 60,230 | 57,262 | 55,951 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $106,470 | $23,612 | $27,461 | $10,161 |
Gross Profit | 89,988 | 16,195 | 24,516 | 9,939 |
EBITDA | 98,709 | -76,400 | -43,542 | -25,526 |
EBIT | 94,655 | -82,789 | -44,548 | -26,470 |
Net Income | 83,229 | -105,511 | -46,049 | -26,772 |
Net Change In Cash | 106,470 | 23,612 | 27,461 | 10,161 |
Free Cash Flow | -2,433 | -69,665 | -33,831 | -18,810 |
Cash | 62,406 | 33,785 | 43,049 | 65,466 |
Basic Shares | 57,262 | 46,251 | 35,452 | 34,488 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $0.25 |
2026-03-31 | $0.18 |
2025-12-31 | $0.19 |
2025-09-30 | -$0.01 |